Related Experiment Videos
123I-methylene blue: an unsatisfactory parathyroid imaging agent
P J Blower1, A G Kettle, M J O'Doherty
1Kent and Canterbury Hospital, UK.
Nuclear Medicine Communications
|July 1, 1992
Summary
123I-labelled methylene blue showed poor performance for parathyroid adenoma imaging. This radiotracer was unsatisfactory compared to standard radionuclide methods for preoperative localization.
Area of Science:
- Nuclear Medicine
- Radiopharmacology
Background:
- Parathyroid adenomas require accurate preoperative localization for surgical planning.
- Established radionuclide imaging agents like thallium-201 (201Tl) and technetium-99m-sestamibi (99Tcm-sestamibi) are commonly used.
Purpose of the Study:
- To evaluate the efficacy of 123I-labelled methylene blue as a novel agent for parathyroid adenoma imaging.
Main Methods:
- A prospective study involving five patients with surgically confirmed parathyroid adenomas.
- Preoperative localization was attempted using 123I-labelled methylene blue.
- Imaging results were compared with those obtained from 201Tl and 99Tcm-sestamibi.
Main Results:
- 123I-labelled methylene blue successfully localized only one of the five parathyroid adenomas.
- The agent yielded negative results in two patients and equivocal uptake in the remaining two.
- Conventional agents (201Tl, 99Tcm-sestamibi) had successfully localized all adenomas preoperatively.
Conclusions:
- 123I-labelled methylene blue is not a satisfactory agent for parathyroid adenoma imaging.
- Its diagnostic performance is inferior to existing radionuclide imaging techniques.